Drug Profile
VBI 1901
Alternative Names: eVLP vaccines - VBI Vaccines; GBM eVLP - VBI; Glioblastoma eVLP Vaccine - VBI Vaccines; Glioblastoma Immunotherapy; MB therapeutic vaccine candidate; Medulloblastoma eVLP Vaccine - VBI Vaccines; Medulloblastoma therapeutic vaccine candidate; VBI-1901Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator VBI Vaccines
- Developer GSK; VBI Vaccines
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- No development reported Medulloblastoma
Most Recent Events
- 03 Apr 2024 Efficacy data from a phase IIb trial in Glioblastoma released by VBI Vaccines
- 14 Feb 2024 VBI Vaccines and Brii Biosciences enters into an exclusive license to develop and commercialize VBI 1901
- 20 Nov 2023 Updated efficacy data from a phase I/II trial in Glioblastoma released by VBI Vaccines